...
首页> 外文期刊>Pharmacogenomics >Impact of biomarkers on clinical trial risk
【24h】

Impact of biomarkers on clinical trial risk

机译:生物标志物对临床试验风险的影响

获取原文
获取原文并翻译 | 示例
           

摘要

The last decade has witnessed the cost of drug development rise dramatically; concurrently, the number of new drug approvals has declined. Clinical trial failure rates have contributed significantly to this 'innovation crisis and are directly related to clinical trial risk. One strategy that is often touted to resolve this challenge depends on embracing a personalized medicine approach where treatment is tailored to a patients unique genetic background. We highlight a new risk-based paradigm of clinical trial risk that evaluates the utility of biomarkers in drug development and their risk mitigation benefits. Furthermore, examples elucidating the current state of biomarker integration during clinical trials and the potential risks posed by doing so will be discussed.
机译:过去十年见证了药物开发成本的急剧上升;同时,新药批准的数量下降了。临床试验失败率显着促成了这一“创新危机”,并且与临床试验风险直接相关。通常被吹捧为解决这一挑战的一种策略取决于采用个性化医学方法,其中针对患者独特的遗传背景量身定制治疗方案。我们重点介绍了一种基于风险的临床试验风险新范例,该范例评估了生物标志物在药物开发中的效用及其减轻风险的益处。此外,将讨论一些示例,这些示例阐明了临床试验期间生物标志物整合的当前状态以及这样做可能带来的潜在风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号